Changes in the fine specificity of gp100((209-217))-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue

Journal of Immunology

Volumn 162, Issue 3, 1999, Pages 1749-1755

  Clay, Timothy M ^a   Custer, Mary C ^a   McKee, Mark D ^a   Parkhurst, Maria ^a   Robbins, Paul F ^a   Kerstann, Keith ^a   Wunderlich, John ^a   Rosenberg, Steven A ^a   Nishimura, Michael I ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

G9 209 PEPTIDE; GLYCOPROTEIN GP 100; HLA A2 ANTIGEN; HLA A2.1 ANTIGEN; MELANOMA ANTIGEN; MELANOMA VACCINE; UNCLASSIFIED DRUG;

ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; HLA SYSTEM; HUMAN; HUMAN CELL; IMMUNOMODULATION; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN MODIFICATION; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; VACCINATION;

AMINO ACID SEQUENCE; BINDING SITES; CANCER VACCINES; EPITOPES; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; T-LYMPHOCYTES;

EID: 0033082514     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Rosenberg, S. A., P. Spiess, and R. Lafreniere. 1986. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1318.
2. Rosenberg, S. A., J. R. Yannelli, J. C. Yang, S. L. Topalian, D. J. Schwartzentruber, J. S. Weber, D. R. Parkinson, C. A. Seipp, J. H. Einhorn, and D. E. White. 1994. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl. Cancer Inst. 86:1159.
3. Yannelli, J. R., C. Hyatt, S. McConnell, K. Hines, L. Jacknin, L. Parker, M. Sanders, and S. A. Rosenberg 1996. Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience. Int. J. Cancer 65: 413.
4. Rosenberg, S. A., J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, M. E. Dudley, S. L. Schwartz, P. J. Spiess, J. R. Wunderlich, M. R. Parkhurst, Y. Kawakami, C.A. Seipp, J. H. Einhorn, and D. E. White. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4:321.
5. Celis, E., V. Tsai, C. Crimi, R. De Mars, P. A. Wentworth, R. W. Chesnut, H. M. Grey, A. Sette, and H. M. Serra. 1994. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc. Natl. Acad. Sci. USA 91:2105.
6. Salgaller, M. L., J. S. Weber, S. Koenig, J. R. Yannelli, and S. A. Rosenberg, 1994. Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide. Cancer Immunol. Immunother. 39:105.
7. Salgaller, M., A. Afshar, F. Marincola, L. Rivoltini, Y. Kawakami, and S. Rosenberg. 1995. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res. 55:4972.
8. Rivoltini, L., Y. Kawakami, K. Sakaguchi, S. Southwood, A. Sette, P. F. Robbins, F. M. Marincola, M. L. Salgaller, J. R. Yannelli, E. Apella, and S. A. Rosenberg 1995. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J. Immunol. 154: 2257.
9. Herman, J., P. van der Bruggen, I. F. Luescher, S. Mandruzzato, P. Romero, J. Thonnard, K. Fleischhauer, T. Boon, and P. G. Coulie. 1996. A peptide encoded by the human MAGE 3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE 3. Immunogenetics 43:377.
10. van der Bruggen, P., J. Bastin, T. Gajewski, P.G. Coulie, P. Boel, C. de Smet, C. Traversari, A. Townsend, and T. Boon. 1994. A peptide encoded by the human MAGE 3 gene and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE 3. Eur. J. Immunol. 24:3038.
11. Kawakami, Y., S. Eliyahu, C. Jennings, K. Sakaguchi, X. Kang, S. Southwood, P. F. Robbins, A. Sette, E. Appella, and S. A. Rosenberg. 1995. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor infiltrating lymphocytes associated with in vivo tumor regression. J. Immunol. 154:3961.
12. Parkhurst, M. R., M. I. Salgaller, S. Southwood, P. F. Robbins, A. Sette, S. A. Rosenberg, and Y. Kawakami. 1996. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J. Immunol. 157:2539.
13. Rosenberg, S. A. Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. 1996. J. Natl. Cancer Inst. 88:1635.
14. Rosenberg, S. A., B. S. Packard, P. M. Aebersold, D. Solomon, S. L. Topalian, S. T. Toy, P. Simon, M. T. Lotze, J. C. Yang, C. A. Seipp, C. Simpson, C. Carter, S. Bock, D. Schwartzentruber, J. P. Wei, and D. E. White. 1988. Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: preliminary report. N. Engl. J. Med. 319:1676.
15. Walter, E. A., P. D. Greenberg, M. J. Gilbert, R. J. Finch, K. S. Watanabe, E. D. Thomas, and S. R. Riddell. 1995. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333:1038.
16. Topalian, S. L., D. Soloman, and S. A. Rosenberg. 1989. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J. Immunol. 142:3714.
17. Kawakami, Y., S. Eliyahu, K. Sakaguhi, P. F. Robbins, L. Rivoltini, J. R. Yannelli, E. Appella, and S. A. Rosenberg. 1994. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 180:347.
18. Kawakami, Y., S. Eliyahu, C. H. Delgado, P. F. Robbins, L. Rivoltini, S. L. Topalian, T. Miki, and S. A. Rosenberg. 1994. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA 91:3515.
19. Cole, D. J., D. P. Weil, P. Shamamian, L. Rivoltini, Y. Kawakami, S. Topalian, C. Jennings, S. Eliyahu, S. A. Rosenberg, and M. I. Nishimura. 1994. Identification of MART-1-specific T-cell receptors: T-cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitope. Cancer Res. 54:5265.
20. Sensi, M., C. Traversari, M. Radrizzani, S. Salvi, C. Maccalli, R. Mortarini, L. Rivoltini, C. Farina, G. Nicolini, T. Wolfel, V. Brichard, T. Boon, C. Bordignon, A. Anichini, and G. Parmiani. 1995. Cytotoxic T lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1. Proc. Natl. Acad. Sci. USA 92:5674.
21. Romero, P., N. Gervois, J. Schneider, P. Escobar, D. Valmori, C. Pannetier, A. Steinle, T. Wolfel, D. Lienard, V. Brichard, A. Van Pel, F. Jotereau, and J-C. Cerottini. 1997. Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma. J. Immunol. 159:2366.
22. Zarour, H., C. De Smet, F. Lehmann, M. Marchand, B. Lethe, P. Romero, T. Boon, and J. C. Renauld. 1996. The majority of autologous cytolytic T lymphocyte clones derived from peripheral blood lymphocytes of a melanoma patient recognize an antigenic peptide derived from Pmel17/gp100. J. Invest. Dermatol. 107:63.
23. Romero, P., C. Pannetier, J. Herman, C. V. Jongeneel, J. C. Cerottini, and P. G. Coulie. 1995. Multiple specificities in the repertoire of a melanoma patient's cytolytic T lymphocytes directed against tumor antigen MAGE-1.A1. J. Exp. Med. 182:1011.
24. Rivoltini, L., K. C. Barrachini, V. Viggiano, Y. Kawakami, A. Smith, A. Mixon, N. P. Restifo, S. L. Topalian, T. B. Simonis, S. A. Rosenberg, and F. M. Marincola. 1995. Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. Cancer Res. 55:3149.
25. Green, J. M., and C. B. Thompson. 1994. Modulation of T cell proliferative response by accessory cell interactions Immunol. Res. 13:234.
26. Griesser, H., and T. W. Mak. 1994. The T-cell receptor-structure, function, and clinical application. Hematol. Pathol. 8:1.
27. Ikeda, H., B. Lethe, F. Lehmann, N. Van Baren, J.-F. Baurain, C. De Smet, H. Chambost, M. Vitale, A. Moretta, T. Boon, and P. G. Coulie. 1997. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6:199.
28. Kersh, G. J., and P. M. Allen. 1996 Essential flexibility in the T-cell recognition of antigen. Nature 380:495.
29. Chen, W., J. McCluskey, S. Rodda, and F. R. Carbone. 1993. Changes at peptide residues buried in the major histocompatibility complex (MHC) class I binding cleft influence T cell recognition: a possible role for indirect conformational alterations in the MHC class I or bound peptide in determining T cell recognition. J. Exp. Med. 177:869.
30. Chen, Y.-Z., S. Matsushita, and Y. Nishimura. 1996. Response of a human T cell clone to a large panel of altered peptide ligands carrying single residue substitutions in an antigenic peptide. J. Immunol. 157:3783.
31. k determinant: single conservative amino acid changes in the complementarity-determining region 3 dramatically alter antigen fine specificity. J. Immunol. 157:2291.
32. Shilyansky, J., M. I. Nishimura, J. R. Yannelli, Y. Kawakami, L. S. Jacknin, P. Charmley, and S. A. Rosenberg. 1994. T-cell receptor usage by melanoma-specific elonal and highly oligoclonal tumor-infiltrating lymphocyte lines. Proc. Natl. Acad. Sci. USA 91:2829.
33. Mizoguchi, H., J. J. O'Shea, D. L. Longo, C. M. Loeffler, D. W. McVicar, and A. C. Ochoa, 1992. Alterations in signal transduction molecules in T lymphocytes from tumor bearing mice. Science 258:1795.
34. lck in T-cells infiltrating human renal cell carinoma. Cancer Res. 53:5613.
35. Nakagomi, H., M. Petersson, I. Magnusson, C. Juhlin, M. Matsuda, H. Mellstedt, J. L. Taupin, E. Vivier, P. Anderson, and R. Kiessling, 1993. Decreased expression of the signal-transducing ζ chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res. 53:5610.
36. Rabinowich, H., M. Banks, T. E. Reichert, T. F. Logan, J. M. Kirkwood, and T. L. Whiteside. 1996. Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy. Clin. Cancer Res. 2:1263.
37. Yoong, K. F., and D. H. Adams. 1998. Interleukin 2 restores CD3-ζ chain expression but fails to generate tumor-specific lysis activity in tumor-infiltrating lymphocytes derived from human colorectal hepatic metastases Br. J. Cancer 77:1072.